10-Q: Labcorp Q3 2025 Earnings Surge on Strong Demand, Acquisitions

Labcorp Holdings Inc. reported a significant increase in Q3 2025 revenues and net earnings, driven by robust organic growth and strategic acquisitions across its Diagnostics and Biopharma segments.

Summary

• Revenues for the three months ended September 30, 2025, increased by 8.6% to $3,563.5 million, up from $3,282.0 million in the prior year period.
• Net earnings attributable to Labcorp Holdings Inc. for the quarter rose by 54.2% to $261.1 million, compared to $169.3 million in Q3 2024.
• Diluted earnings per share (EPS) for Q3 2025 were $3.12, a 56.0% increase from $2.00 in Q3 2024.
• Operating income for the quarter increased by 56.1% to $396.6 million, up from $254.1 million in Q3 2024.
• For the nine months ended September 30, 2025, revenues increased by 7.8% to $10,435.9 million, and net earnings attributable to Labcorp Holdings Inc. grew by 18.1% to $711.8 million.
• Net cash provided by operating activities for the nine months ended September 30, 2025, was $1,026.3 million, an increase from $808.6 million in the prior year period.
• The company acquired several businesses for $324.0 million in cash during the nine months ended September 30, 2025, including a 15% minority interest in SYNLAB for $151.6 million.
• Agreements were entered into to acquire select assets from Community Health Systems, Inc. for approximately $195.0 million (anticipated Q4 2025 close) and Empire City Laboratories, Inc. for up to $250.0 million (anticipated Q1 2026 close).
• The Transition Services Agreement (TSA) with Fortrea Holdings Inc. expired on June 30, 2025, resulting in a $18.4 million decrease in fees charged to Fortrea for Q3 2025.
• The company repurchased 0.9 million shares of its common stock for $225.0 million during the nine months ended September 30, 2025, with $1,055.4 million remaining under the current authorization.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue and earnings growth, improved operating margins, and strategic acquisitions. Shareholder returns through dividends and buybacks are also positive. However, a notable decrease in cash and cash equivalents, increased interest expense, and ongoing, potentially costly legal challenges temper the overall positive sentiment.

Positives

• Strong revenue growth of 8.6% in Q3 2025, driven by 6.2% organic growth and 1.7% from acquisitions, net of divestitures.
• Significant increase in net earnings attributable to Labcorp Holdings Inc. by 54.2% in Q3 2025.
• Diluted EPS increased by 56.0% in Q3 2025, reflecting strong profitability.
• Operating income surged by 56.1% in Q3 2025, indicating improved operational efficiency.
• Cost of revenues as a percentage of revenues decreased to 71.2% in Q3 2025 from 72.4% in Q3 2024, primarily due to operational efficiencies and revenue growth.
• Selling, general, and administrative expenses as a percentage of revenues decreased to 15.5% in Q3 2025 from 17.3% in Q3 2024, partly due to reduced Spin-off related costs.
• Net cash provided by operating activities increased by $217.7 million for the nine months ended September 30, 2025, primarily due to higher earnings.
• Net cash used for investing activities decreased by $353.1 million for the nine months ended September 30, 2025, mainly due to fewer business acquisitions and lower capital expenditures compared to the prior year.
• Restructuring and other charges decreased significantly by 66.4% in Q3 2025 and 52.6% for the nine months ended September 30, 2025.

Negatives

• Cash and cash equivalents decreased significantly to $598.1 million at September 30, 2025, from $1,518.7 million at December 31, 2024.
• Net cash used for financing activities was $1,166.6 million for the nine months ended September 30, 2025, a substantial shift from $1,326.6 million provided in the prior year, primarily due to decreased senior note offerings and increased payments.
• Interest expense increased by 10.9% in Q3 2025 and 16.7% for the nine months ended September 30, 2025, due to higher weighted-average interest rates and increased average total debt outstanding.
• Equity method loss, net, increased significantly to $5.2 million in Q3 2025 and $7.2 million for the nine months ended September 30, 2025, primarily due to the loss recognized from the SYNLAB investment.
• The 'Other, net' category saw a negative change of $143.8 million in Q3 2025 and $181.2 million for the nine months ended September 30, 2025, largely due to the expiration of the TSA with Fortrea and investment losses.
• The enactment of the One Big Beautiful Bill Act (OBBBA) on July 4, 2025, could lead to revised regulatory requirements and reduced federal funding, potentially causing a decline in utilization of diagnostic testing services and decreased revenue, though management believes the impact will not be material.

Risks

• Changes in government and third-party payer regulations, reimbursement, or coverage policies, including the impact of the U.S. Protecting Access to Medicare Act of 2014.
• Significant monetary damages, fines, penalties, and reputational damage from enforcement of anti-fraud and abuse laws.
• Fines, penalties, and reputational damage from failure to comply with privacy and security laws and regulations, such as HIPAA and GDPR.
• Loss or suspension of licenses or imposition of fines under applicable licensing laws for clinical laboratories and laboratory-developed tests (LDTs).
• Penalties or loss of license from failure to comply with occupational and workplace safety laws.
• Sanctions or other remedies from failure to comply with the Animal Welfare Act or related regulations.
• Increased competition, including price competition, competitive bidding, and changes to fee schedules.
• Changes in payer mix or payment structure, including increased member cost-sharing and adverse changes in payer coverage policies.
• Failure to retain or attract business from managed care organizations (MCOs).
• Inability to achieve expected benefits and synergies from newly acquired businesses, including due to items not discovered in due diligence.
• Termination, loss, delay, reduction in scope, or increased costs of contracts.
• Liability arising from errors or omissions in the performance of testing and other services.
• Disruption in the provision or transportation of services or supplies by third parties.
• Damage or disruption to facilities due to natural disasters, geopolitical crises, or public health crises.
• Adverse results in litigation matters, including patent infringement (Ravgen), class actions (AMCA, ADA, Meta Pixel), and government inquiries (Texas Medicaid, DOJ).
• Inability to attract, retain, and develop experienced and qualified personnel.
• Failure in information technology systems, including cybersecurity incidents, or adverse effects from the use of artificial intelligence and machine learning tools.
• Business interruption and increased costs due to unionization of employees, strikes, or labor unrest.
• Failure to maintain days sales outstanding levels, cash collections, profitability, and/or reimbursement due to unfavorable changes in third-party payer policies.
• Impact on revenues and cash collections from a significant deterioration in the economy or financial markets.
• Failure to maintain the expected capital structure, including investment grade rating or leverage ratio covenants.
• Changes in reimbursement by foreign governments and foreign currency fluctuations.
• Expenses and risks associated with international operations, including compliance with anti-corruption laws and trade sanction laws.
• Changes in tax laws and regulations or changes in their interpretation.

Future Outlook

The company anticipates closing the acquisition of select assets from Community Health Systems, Inc. in the fourth quarter of 2025 and the acquisition of select clinical laboratory assets from Empire City Laboratories, Inc. in the first quarter of 2026, both subject to customary closing conditions and regulatory approvals. Management believes that while the One Big Beautiful Bill Act (OBBBA) could lead to reduced federal funding and a decline in diagnostic testing utilization, any such reduction is not likely to have a material impact on future results of operations.

Management Comments

• Management believes that any potential reduction in diagnostic testing utilization due to the One Big Beautiful Bill Act (OBBBA) would not likely have a material impact on the company's results of operations in future periods.

Industry Context

The company operates in a dynamic healthcare industry characterized by ongoing consolidation, technological advancements, and evolving regulatory landscapes. Its strong organic growth in both Diagnostics and Biopharma Laboratory Services segments, coupled with strategic acquisitions, indicates a proactive approach to market expansion and service diversification. The expiration of the Transition Services Agreement with Fortrea marks a further step in the company's strategic realignment post-spin-off. The industry continues to face scrutiny over billing practices and data privacy, as evidenced by the company's ongoing legal proceedings.

Legal Proceedings

• Texas Medicaid Lawsuit: The Texas Court of Appeals reversed a District Court's summary judgment in favor of the company. The company filed a Petition for Review with the Texas Supreme Court on February 28, 2025, and will vigorously defend the lawsuit.
• Patty Davis v. Labcorp (Florida Consumer Collection Practices Act): A Final Judgment Approving Settlement Agreement was entered on August 13, 2025, certifying a class and approving fees.
• AMCA Incident (Data Breach) Multidistrict Litigation: Consolidated class action lawsuits are ongoing, alleging inadequate data protection and delayed notification. The court granted in part and denied in part the company's Motion to Dismiss on May 5, 2023. Plaintiffs served a motion for class certification on November 1, 2024. The company will vigorously defend the remaining claims.
• Raymond Eugenio, Derivatively on Behalf of Nominal Defendant, Laboratory Corporation of America Holdings v. Lance Berberian, et al. (Shareholder Derivative Lawsuit): This lawsuit, related to the AMCA Incident, is stayed pending the resolution of the multidistrict litigation.
• Luke Davis and Julian Vargas, et al. v. Laboratory Corporation of America (ADA Kiosk Accessibility): The Ninth Circuit affirmed class certification on February 8, 2024. The company's Petition for Writ of Certiorari to the US Supreme Court was granted on January 24, 2025, but later dismissed on June 5, 2025. The company will vigorously defend the lawsuit.
• Ravgen Inc. v. Laboratory Corporation of America Holdings (Patent Infringement): A jury verdict on September 28, 2022, found willful infringement and awarded $272.0 million in damages. The court awarded enhanced damages of $100.0 million on May 12, 2023, and post-verdict supplemental damages of $2.6 million plus an ongoing royalty on January 23, 2025. The company filed an appeal and an appeal bond on March 18, 2025, and strongly disagrees with the verdict.
• Jose Bermejo v. Laboratory Corporation of America (California Labor Code): The court granted final approval of settlements in both Bermejo I and Bermejo II lawsuits on October 15, 2025.
• Connie Howard, Yadira Yazmin Hernandez, and Deborah Reynolds, et al. v. Laboratory Corporation of America, Laboratory Corporation of America Holdings, and Meta Platforms, Inc. (Meta Pixel Tracking): The court denied the company's Motion to Dismiss the Amended Complaint on September 27, 2024. The company will vigorously defend the lawsuit.
• Governmental Inquiries: The company is cooperating with subpoenas from the State of Colorado Office of the Attorney General related to urine drug testing and from the Department of Justice in Camden, New Jersey, related to non-invasive prenatal screening tests, and in Boston, Massachusetts, related to urine drug testing.

Stakeholder Impact

• Shareholders: Benefited from increased net earnings and EPS, ongoing share repurchase program, and declared cash dividends. Exposed to risks from ongoing legal proceedings and potential impacts of the OBBBA.
• Employees: Affected by restructuring charges, though these have decreased. Participate in employee stock plans.
• Customers: Benefit from expanded services through acquisitions and organic growth. Potential impact from changes in healthcare regulations and funding under the OBBBA.
• Creditors: The company remains in compliance with all covenants under its credit facilities and indentures, indicating sound debt management.
• Regulatory Bodies: The company is subject to numerous inquiries and lawsuits related to billing practices, data privacy, and patent infringement, highlighting ongoing regulatory scrutiny in the healthcare sector.

Next Steps

• Closing of the acquisition of select assets from Community Health Systems, Inc. in the fourth quarter of 2025.
• Closing of the acquisition of select clinical laboratory assets from Empire City Laboratories, Inc. in the first quarter of 2026.
• Payment of a cash dividend of $0.72 per share on December 11, 2025, to stockholders of record as of November 26, 2025.
• Vigorously defending ongoing legal proceedings, including the Texas Medicaid lawsuit, AMCA Incident multidistrict litigation, Luke Davis and Julian Vargas lawsuit, Ravgen Inc. patent infringement lawsuit, and Meta Pixel tracking lawsuit.

Key Dates

Recommendation

The company demonstrated robust financial performance in Q3 2025, with significant year-over-year increases in revenue, net earnings, and diluted EPS, driven by strong organic growth and strategic acquisitions. Operating margins improved across both key segments. While cash and cash equivalents decreased due to substantial debt payments and share repurchases, the company maintains strong liquidity with available credit facilities and is in compliance with all debt covenants. The ongoing share repurchase program and consistent dividends signal a commitment to shareholder returns. Although there are several ongoing legal challenges, the core business performance and strategic expansion initiatives present a compelling investment case for long-term growth.

Keywords

Labcorp, LH, Diagnostics, Biopharma, Laboratory Services, SEC Filing, 10-Q, Earnings, Revenue, Acquisitions, Healthcare, Medical Testing, Financial Results, Q3 2025